Lily Chang

Regulatory risk is one of the most critical variables investors evaluate when allocating capital to biotechnology and pharmaceutical companies. These industries are uniquely dependent on government agencies for product approval, labeling, manufacturing standards, and post-market surveillance. A single regulatory decision can determine whether a drug becomes a blockbuster, remains delayed for years, or never reaches patients at all.From an investor’s perspective, regulatory risk reflects the probability that a product or company will face approval delays, restrictive conditions, unexpected compliance costs, or outright rejection. Assessing this risk requires a combination of scientific literacy, regulatory knowledge, and financial analysis.The Role of Regulatory…

Corporate venture capital arms, commonly known as CVCs, have long operated where finance meets strategy, yet recent years have seen their investment philosophies shift noticeably under the influence of market turbulence, rapid technological progress, and evolving expectations from their parent firms, transforming what was once chiefly about strategic proximity into a more rigorous, analytics‑focused, and globally attuned model.Transforming Strategic Flexibility into Tangible ValueHistorically, many corporate venture arms invested to gain early exposure to emerging technologies, even when the financial case was uncertain. Today, boards and chief financial officers increasingly expect clear value creation, both strategic and financial.The principal modifications encompass:Dual…